Human Vaccines & Immunotherapeutics (Jan 2023)

Effectiveness of vero cell inactivated vaccine against severe acute respiratory infections (SARI) in Sibu, Malaysia: A retrospective test-negative design

  • Teck-Hock Toh,
  • Yang-Yang Qi,
  • Sook-Min Yong,
  • Jeffrey Soon-Yit Lee,
  • Nur Fatin Liyana,
  • Raymond Yon-Han See,
  • Jo-Hun Teh,
  • Aw-Zien Toh,
  • Lin Naing,
  • Kamilah Dahian,
  • Jun-Wei Liew,
  • Caisha Nivenia Mose,
  • Malvina Zi-Qing Yong,
  • Ngiik-Jing Ling,
  • Diana Wang-Sing Chua,
  • Wee-Wei Ling,
  • Nanthakumar Thirunavukkarasu,
  • Mohd Raili Suhaili,
  • Jie-Lai Xia,
  • John Clemens,
  • Xuan-Yi Wang

DOI
https://doi.org/10.1080/21645515.2023.2167438
Journal volume & issue
Vol. 19, no. 1

Abstract

Read online

The effectiveness of the vero cell inactivated vaccine (CoronaVac®) against severe acute respiratory infection (‎SARI)‎ caused by SARS-CoV-2 in the real world was assessed. A matched test-negative case-control design was employed using the web-based national information system, as well as the hospitalization dataset in Sibu Hospital. Vaccine effectiveness was measured by conditional logistic regression with adjustment for gender, underlying comorbidity, smoking status, and education level. Between 15 March and 30 September 2021, 838 eligible SARI patients were identified from the hospitalization records. Vaccine effectiveness was 42.4% (95% confidence interval [CI]: −28.3 to 74.1) for partial vaccination (after receiving the first dose to 14 days after receiving the second dose), and 76.5% (95% CI: 45.6 to 89.8) for complete vaccination (at 15 days or more after receiving the second dose). This analysis indicated that two doses of CoronaVac® vaccine provided efficacious protection against SARI caused by SARS-CoV-2 in the short term. However, the duration of protection, and performance against new variants need to be studied continuously.

Keywords